KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Inventory (2018 - 2025)

Adaptive Biotechnologies' Inventory history spans 8 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Inventory rose 16.35% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, up 16.35%, while the annual FY2025 figure was $9.8 million, 16.35% up from the prior year.
  • Inventory for Q4 2025 was $9.8 million at Adaptive Biotechnologies, down from $9.9 million in the prior quarter.
  • Across five years, Inventory topped out at $21.0 million in Q1 2022 and bottomed at $8.4 million in Q2 2025.
  • The 5-year median for Inventory is $15.9 million (2022), against an average of $15.1 million.
  • The largest annual shift saw Inventory soared 76.65% in 2021 before it crashed 41.58% in 2024.
  • A 5-year view of Inventory shows it stood at $19.3 million in 2021, then fell by 24.97% to $14.5 million in 2022, then dropped by 0.03% to $14.4 million in 2023, then tumbled by 41.58% to $8.4 million in 2024, then rose by 16.35% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Inventory are $9.8 million (Q4 2025), $9.9 million (Q3 2025), and $8.4 million (Q2 2025).